




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Diabetes Research and Clinical Practice

journal homepage: www.journals.elsevier.com/diabetes-research-and-clinical-practice

Editorial

Diabetes Research and Clinical Practice and the fight against COVID-19



ARTICLE INFO

The COVID-19 pandemic is still affecting the entire world. People with diabetes are paying a huge price to this disease [1]. Data show a higher incidence of COVID-19 in people with diabetes and a worse prognosis [1]. Moreover, preliminary evidence suggests that COVID-19 may contribute to the appearance of diabetes by itself [2].

The scientific community worked hard to fight COVID-19 and *Diabetes Research and Clinical Practice* (DRCP) played a part.

Since publishing a call for articles related to COVID-19 and diabetes, DRCP has published, at the time of writing, no fewer than 153 papers on the topic [3]. Furthermore, I believe that DRCP also helped in opening new options for research. The possible role of hyperglycemia in worsening the prognosis of the disease [4], the possibility that COVID-19 in diabetes could have been, in some respects, similar to what is known for other acute pathologies [5], and to be reassured about the use of standard medications if affected by COVID-19 [6], have been anticipated by DRCP and confirmed by published articles [7–11]. Additionally, the hypothesis that glycemic control could affect the response of people with diabetes to vaccination was mooted in DRCP [12] and recently confirmed [13].

As Editor of DRCP, therefore, I feel proud about the role it has played in fighting the COVID-19 in people with diabetes. I have also to admit that this approach has contributed to the significant increase of the Journal Impact Factor, which this year increased from 5.602 to 8.180, placing the Journal 20th of 146 journals in the category ‘Endocrinology & Metabolism’. For me, it is also the opportunity to thank all who have contributed to this success: the Associate Editors, the Elsevier team and our important partner, the International Diabetes Federation (IDF). Indeed, one of the most-cited articles has been that written by the President of the IDF with two co-authors [14]. The importance of the IDF affiliation to DRCP, of course, is much broader and deeper than this [15].

In conclusion, DRCP has helped lead the way in the fight against COVID-19, which is part of its broader mission: to help advance the understanding and treatment of diabetes worldwide.

References

- [1] Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, et al. Promoting a syndemic approach for cardiometabolic disease management during COVID-19-19: The CAPISCO international expert panel. *Front Cardiovasc Med* 2021;8:78776. <https://doi.org/10.3389/fcvm.2021.787761>.
- [2] Gentile S, Strollo F, Mambro A, Ceriello A. COVID -19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them? *Diabetes Obes Metab* 2020;22:2507–8. <https://doi.org/10.1111/dom.14170>.
- [3] Source: Science Direct, accessed July 19th 2022.
- [4] Ceriello A. Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. *Diabetes Res Clin Pract* 2020;163:108186. <https://doi.org/10.1016/j.diabres.2020.108186>.
- [5] Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new? *Diabetes Res Clin Pract* 2020;167:108383. <https://doi.org/10.1016/j.diabres.2020.108383>.
- [6] Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? *Diabetes Res Clin Pract* 2020;163:108151. <https://doi.org/10.1016/j.diabres.2020.108151>.
- [7] Ceriello A, De Nigris V, Prattichizzo F. Why is hyperglycaemia worsening COVID-19 and its prognosis? *Diabetes Obes Metab* 2020;22:1951–2. <https://doi.org/10.1111/dom.14098>.
- [8] Ceriello A. Lessons from COVID-19: How human behaviour may influence the science. *Diabetes Res Clin Pract* 2020;169:108491. <https://doi.org/10.1016/j.diabres.2020.108491>.
- [9] Ceriello A, Standl E, Catrinou D, Itzhak B, Lalic NM, Rahelic D, et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. *Diabetes Care* 2020;43:1427–32. <https://doi.org/10.2337/dc20-0941>.
- [10] Caballero AE, Ceriello A, Misra A, Aschner P, McDonnell ME, Hassanein M, et al. COVID-19 in people living with diabetes: An international consensus. *J Diabetes Complications* 2020;34(9):107671.
- [11] Ceriello A, Standl E, Catrinou D, Itzhak B, Lalic NM, Rahelic D, et al. Issues for the management of people with diabetes and COVID-19 in ICU. *Cardiovasc Diabetol* 2020;19(1).
- [12] Ceriello A. Diabetes, SARS-CoV-2/COVID-19 vaccines and glycemic control: Call for data. *Diabetes Res Clin Pract* 2021;174:108741. <https://doi.org/10.1016/j.diabres.2021.108741>.
- [13] Marfella R, Sardu C, D'Onofrio N, Prattichizzo F, Scisciola L, Messina V, et al. Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. *Nat Commun* 2022;13:2318. <https://doi.org/10.1038/s41467-022->
- [14] Hussain A, Bhowmik B, do Vale Moreira NC. 30068-2. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract* 2020;162:108142. <https://doi.org/10.1016/j.diabres.2020.108142>.
- [15] Hussain A, Boulton AJM. COVID-19 and diabetes: International Diabetes Federation perspectives. *Diabetes Res Clin Pract* 2020;167:108339. <https://doi.org/10.1016/j.diabres.2020.108339>.

Abbreviations: DRCP, Diabetes Researc & Clinical Practice; IDF, International Diabetes Federation.

<https://doi.org/10.1016/j.diabres.2022.110025>

Available online 27 July 2022

0168-8227/© 2022 Elsevier B.V. All rights reserved.

Antonio Ceriello*
IRCCS MultiMedica, Milan, Italy

* Address: IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138
Milan, Italy.
E-mail address: antonio.ceriello@hotmail.it.